ARCA biopharma Submits Patent Application to US Patent and Trademark Office for Atrial Fibrillation

ARCA biopharma (NASDAQ:ABIO) has announced it has filed a provisional patent application with the US Patent and Trademark Office covering...

ARCA biopharma Shares Published Paper Showing Trial Results

ARCA biopharma announced the publication of a paper showing GENETIC-AF Phase 2B trial results.

ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

ARCA biopharma (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced...

ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

ARCA Biopharma (NASDAQ:ABIO) has announced it has received guidance from the US Food and Drug Administration (FDA) following an End-of-Phase...